Company intelligence / Profile preview

TRIN Pharma

Baar, Zug, Switzerland

Ownership: Private
Development stage: Other

Overview

TRIN Pharma is a Swiss clinical-stage biotechnology company focused on developing novel small molecule therapeutics for the treatment of cancer. The company's lead program, TRIN-271, is a first-in-class activator of the mitochondrial protease ClpP, designed to induce mitochondrial dysfunction and cell death in malignant cells. TRIN Pharma targets hematological malignancies, specifically acute myeloid leukemia (AML), as well as various solid tumors. By leveraging mitochondrial stress responses, the company aims to provide new treatment options for patients with difficult-to-treat cancers.

Therapeutic areas: HematologyOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on TRIN Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRIN Pharma.

Explore the full profile